drugset / Trial / NCT04941781

PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

NCT04941781 ↗

Phase 1 Completed 6 enrolled Contineum Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.

Timeline

Start
2021-09-01
Primary completion
2021-11-10
Completion
2021-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PIPE-307 Unknown — Oral

Indications